Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
University of Chinese Academy of Sciences, Beijing, People's Republic of China.
Emerg Microbes Infect. 2020 Dec;9(1):1170-1173. doi: 10.1080/22221751.2020.1772676.
The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined the antiviral abilities of three broad-spectrum antiviral compounds gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. We found that all three tested compounds inhibited viral replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of gemcitabine was suppressed efficiently by the cytidine nucleosides. Additionally, combination of gemcitabine with oxysophoridine had an additive antiviral effect against SARS-CoV-2. Our results demonstrate that broad-spectrum antiviral compounds may have a priority for the screening of antiviral compounds against newly emerging viruses to control viral infection.
在中国爆发的病毒性肺炎相关的新型 SARS-CoV-2 感染正在全球范围内持续。目前尚无批准的抗病毒疗法来治疗这种病毒性疾病。在这里，我们在细胞培养中研究了三种广谱抗病毒化合物吉西他滨、石蒜碱和氧化槐定碱对 SARS-CoV-2 的抗病毒能力。我们发现，这三种测试的化合物在非细胞毒性浓度下均能抑制 Vero-E6 细胞中的病毒复制。吉西他滨的抗病毒作用被胞苷核苷有效地抑制。此外，吉西他滨与氧化槐定碱联合使用对 SARS-CoV-2 具有相加的抗病毒作用。我们的结果表明，广谱抗病毒化合物可能优先用于筛选针对新出现病毒的抗病毒化合物，以控制病毒感染。
